HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup
The Week

Another setback for Ipsen's Albireo portfolio as Bylvay flunks phase 3 trial

Three years after gaining three liver disease assets in its $952 million buyout of Albireo, Ipsen is struggling to develop the trio. The company has reported the failure of liver disease drug Bylvay in a phase 3 study in biliary atresia.

By FiercePharma · Jul 27, 2026 · via FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug
Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease …
Jul 27, 2026
FDA clears zidesamtinib in pretreated ROS1-positive NSCLC, ahead of goal date
The WeekBriefing
FDA clears zidesamtinib in pretreated ROS1-positive NSCLC, ahead of goal date
Nuvalent’s Jideytro won FDA approval for adults with locally advanced or metastatic ROS1-positive NSCLC after …
Jul 27, 2026
The WeekBioPharma Dive ↗
From confidence to capital: Positioning biotech for the next growth cycle
How can biotechs be investor ready? Key takeaways from BIO International and DIA China 2026.…
Jul 27, 2026